Release Date: September 12, 2025
Expiration Date: September 12, 2026
Activity Overview
Prostate cancer continues to pose substantial clinical challenges, with increasing incidence and mortality rates in the United States. While PSMA-directed radioligand therapy (RLT) and advanced imaging technologies have transformed the diagnosis and treatment of metastatic prostate cancer, knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education. To address these unmet needs, PER® has developed this online activity that features expert video interviews.
Target Audience
This activity is directed toward medical oncologists, urologists, radiation oncologists, nuclear medicine physicians, advanced practice providers, nurses, nurse navigators, and palliative care specialists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify barriers to receiving PSMA-directed radioligand therapy and strategies to expand access in the community setting
- Devise strategies to overcome disparities in care and ensure equitable access to novel radioligand therapies in patients with mCRPC
- Incorporate biomarker and imaging-based tools to guide multidisciplinary care and optimize outcomes with PSMA-targeted radioligand therapy
Jeremie Calais, MD, PhD
Director, Clinical Research and Theranostics Programs
Associate Professor
Ahmanson Translational Theranostics Division
Department of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics, Coretag, Curium Pharma, DS Pharma, FibroGen, GE HealthCare, IBA RadioPharma, IsoRay, Janssen Pharmaceuticals, Lantheus, Lightpoint Medical, Mariana, Monrol, Novartis, Nucleus Radiopharma, Pfizer, POINT Biopharma, Progenics, RadioMedix, Radiopharm Theranostics, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceuticals; Grant/Research Funding: Fusion, Lantheus, Novartis, POINT Biopharma, Telix Pharmaceuticals
Tanya B. Dorff, MD
Section Chief, Genitourinary Disease Program
Vice Chair for Clinical Affairs
Professor of Medicine
Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas, AstraZeneca, Bayer, Janssen, Novartis, Pfizer; Research Funding to institution: AbbVie, Amgen, AstraZeneca, Dendreon
Nerina McDonald, MSPAS, PA-C
Teaching Associate
Division of Hematology and Oncology
University of Washington School of Medicine
Physician Assistant, Certified
Fred Hutchinson Cancer Center
Seattle, WA
Nerina McDonald, MSPAS, PA-C, has no relevant financial relationships with ineligible companies.
Scott T. Tagawa, MD, MS, FACP, FASCO
Professor of Medicine and Urology
Weill Cornell Medicine
Attending Physician
New York-Presbyterian/Weill Cornell Medical Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abdera, AIkido Pharma, Amgen, Bayer AG, Biohaven, Blue Earth Diagnostics, Boston Scientific, Clarity Pharmaceuticals, Clovis Oncology, Convergent Therapeutics, Daiichi Sankyo, Eisai Co, EMD Serono, Endocyte, Genentech, General Electric, Genomic Health, Immunomedics, Janssen, Karyopharm Therapeutics, Lantheus, Medivation/Astellas Pharma, Merck, Myovant Sciences, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seagen, Telix Pharmaceuticals, Tolmar, TransThera; Grant/Research Funding: AbbVie, AIQ, Ambrx, Ambrx Biopharma, Amgen, Astellas Pharma, AstraZeneca, Bayer AG, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis Oncology, Endocyte, Gilead Sciences, Immunomedics, Janssen, Janux, Karyopharm Therapeutics, Medivation, Merck, Novartis, POINT Biopharma, Sanofi, Seagen, Telix; Royalty or Patent Benefits: Convergent, Gilead; Ownership interests in privately held companies: Convergent
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.